Optimization of Heart Failure Management Using OptiVol Fluid Status Monitoring and CareLink - OptiLink HF
The goal of the trial was to evaluate a strategy of telemonitoring of fluid status compared with no telemonitoring among subjects who received an implantable cardioverter-defibrillator (ICD). Implanted ICDs had the capability to monitor fluid status and send alerts to physicians based on pre-established fluid criteria.
Contribution to the Literature: The OptiLink-HF trial failed to show that telemonitoring of heart failure patients through ICDs improved outcomes.
Subjects with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) versus no telemonitoring (n = 497).
- Implantation of an ICD or cardiac resynchronization therapy (CRT)-ICD and one additional high-risk characteristic:
- Heart failure hospitalization within the last 12 months
- Diuretic therapy within the last 30 days
- Increased B-type natriuretic peptide (BNP) or N-terminal pro-BNP within the last 30 days
- Total number of enrollees: 1,002
- Duration of follow-up: mean 23 months
- Mean patient age: 66 years
- Percentage female: 23%
- Serum creatinine >2.5 mg/dl or hemodialysis
- Chronic obstructive pulmonary disease
Approximately 75% of alerts were successfully transmitted from the patient’s ICD to a physician, with a resultant medication change in 30%.
The primary outcome of all-cause mortality or cardiovascular hospitalization occurred in 45.0% of the telemonitoring group versus 48.1% of the no telemonitoring group (p = 0.13). There was no treatment interaction among tested subgroups.
- All-cause death: 6.2% with telemonitoring vs. 8.5% with no telemonitoring (p = 0.52)
- Cardiovascular hospitalization: 42.4% with telemonitoring vs. 44.5% with no telemonitoring (p = 0.22)
Among patients with heart failure and implantation of an ICD capable of monitoring fluid status and sending alerts to physicians, telemonitoring did not improve outcomes compared with standard care. Optimal management of advanced heart failure patients remains challenging.
Presented by Dr. Michael Boehm at the European Society of Cardiology Congress, London, September 1, 2015.
Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Heart Failure and Cardiomyopathies, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Heart Failure and Cardiac Biomarkers
Keywords: Arrhythmias, Cardiac, Cardiac Resynchronization Therapy, Defibrillators, Implantable, Diuretics, Heart Failure, Natriuretic Peptide, Brain, Peptide Fragments, Renal Dialysis, ESC Congress
< Back to Listings